https://orcid.org/0000-0002-1311-5216
References
- Renouf DJ, Velazquez-Martin JP, Simpson R, et al. Ocular toxicity of targeted therapies. J Clin Oncol. 2012;30(26):3277–3286.
- Fu C, Gombos DS, Lee J, et al. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. 2017;8(35):58709–58727.
- Schmid KE, Kornek GV, Scheithauer W, et al. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol. 2006;51(1):19–40.
- Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275.
- Robak P, Drozdz I, Szemraj J, et al. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199–208.
- Palumbo A, Mateos MV, Bringhen S, et al. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Blood Rev. 2011;25(4):181–191.
- SEER Cancer Statistics. Cancer Stat Facts: Myeloma. 2020; [cited 2020 July 23]. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html.
- Delforge M, Dhawan R, Robinson D, Jr, et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol. 2012;89(1):16–27.
- Celgene Europe BV. Imnovid 1 mg hard capsules [package insert]. 2013; [cited 2021 April 8]. Available from: https://www.ema.europa.eu/en/documents/product-information/imnovid-epar-product-information_en.pdf.
- Celgene Corporation. REVLIMID [package insert]. 2019; [cited 2021 April 8]. Available from: http://www.celgene.com/content/uploads/revlimid-pi.pdf.
- GlaxoSmithKline. BLENREP [package insert]. 2020; [cited 2021 April 8]. Available from: https://gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Blenrep/pdf/BLENREP-PI-MG.PDF.
- Takeda Pharmaceutical Company Ltd. NINLARO capsules [package insert] 2015; [cited 2021 April 8]. Available from: https://www.ninlaro.com/prescribing-information.pdf.
- Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. 2017;31(9):1915–1921.
- WHO. Classification of Diseases (ICD). 2020; [cited 2021 April 8]. Available from: https://www.who.int/classifications/icd/en/.
- Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–221.